Evidence map›Paper›PMID 38947073›Full record

ArticleResearch square2024

Evaluation of Aav Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy.

Alka Yadav, Rich Liang, Kelly Press, Annika Schmidt, Zahra Shabani, Kun Leng, Calvin Wang, Abinav Sekhar, Joshua Shi, Garth W Devlin and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alka YadavUniversity of California, San Francisco.
Rich LiangUniversity of California, San Francisco.
Kelly PressUniversity of California, San Francisco.
Annika SchmidtUniversity of California, San Francisco.
Zahra ShabaniUniversity of California, San Francisco.
Kun LengUniversity of California, San Francisco.
Calvin WangUniversity of California, San Francisco.
Abinav SekharUniversity of California, San Francisco.
Joshua ShiUniversity of California, San Francisco.
Garth W DevlinDuke University School of Medicine.
Trevor J GonzalezDuke University School of Medicine.
Aravind AsokanDuke University School of Medicine.
Hua SuUniversity of California, San Francisco.

Funding

Uncover the Pathogenesis of Brain Arteriovenous MalformationR01NS027713 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SU, HUA · 1990 to 2023
$8.6M
Reduction of Brain AVM Severity through Inhibition of Pathogenic AngiogenesisR01NS112819 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SU, HUA · 2020 to 2024
$2.9M
NINDS NIH HHS R01 NS027713NINDS NIH HHS R01 NS112819
6 · The paper itself

Abstract

Nosebleeds and intracranial hemorrhage from brain arteriovenous malformations (bAVMs) are among the most devastating symptoms of patients with hereditary hemorrhagic telangiectasis (HHT). All available managements have limitations. We showed that intravenous delivery of soluble FMS-related tyrosine kinase 1 using an adeno-associated viral vector (AAV9-sFLT1) reduced bAVM severity of

Indexed as

Adeno-associated viral vectorAlk1brain arteriovenous malformationgene therapyhereditary hemorrhagic telangiectasia

Identifiers

PMID38947073
PMCPMC11213183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.